Murilo W Dib1, Rachel Riera, Marcos B Ferraz. 1. Centro Paulista de Economia da Saúde (CPES), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Abstract
OBJECTIVES: To estimate the direct annual cost of systemic arterial hypertension (SAH) treatment in Brazil's public and private health care systems, assess its economic impact on the total health care budget, and determine its proportion of the 2005 gross domestic product (GDP). METHODS: A decision tree model was used to determine direct costs based on estimated use of various resources in SAH diagnosis and care, including treatment (medication and non-medication), complementary exams, doctor visits, nutritional assessments, and emergency room visits. RESULTS: Estimated direct annual cost of SAH treatment was approximately US$ 398.9 million for the public health care system and US$ 272.7 million for the private system, representing 0.08% of the 2005 GDP (ranging from 0.05% to 0.16%). With total health care expenses comprising about 7.6% of Brazil's GDP, this cost represented 1.11% of overall health care costs (0.62% to 2.06%)-1.43% of total expenses for the Unified Healthcare System (Sistema Unico de Saúde, SUS) (0.79% to 2.75%) and 0.83% of expenses for the private health care system (0.47% to 1.48%). Conclusion. To guarantee public or private health care based on the principles of universality and equality, with limited available resources, efforts must be focused on educating the population on prevention and treatment compliance in diseases such as SAH that require significant health resources.
OBJECTIVES: To estimate the direct annual cost of systemic arterial hypertension (SAH) treatment in Brazil's public and private health care systems, assess its economic impact on the total health care budget, and determine its proportion of the 2005 gross domestic product (GDP). METHODS: A decision tree model was used to determine direct costs based on estimated use of various resources in SAH diagnosis and care, including treatment (medication and non-medication), complementary exams, doctor visits, nutritional assessments, and emergency room visits. RESULTS: Estimated direct annual cost of SAH treatment was approximately US$ 398.9 million for the public health care system and US$ 272.7 million for the private system, representing 0.08% of the 2005 GDP (ranging from 0.05% to 0.16%). With total health care expenses comprising about 7.6% of Brazil's GDP, this cost represented 1.11% of overall health care costs (0.62% to 2.06%)-1.43% of total expenses for the Unified Healthcare System (Sistema Unico de Saúde, SUS) (0.79% to 2.75%) and 0.83% of expenses for the private health care system (0.47% to 1.48%). Conclusion. To guarantee public or private health care based on the principles of universality and equality, with limited available resources, efforts must be focused on educating the population on prevention and treatment compliance in diseases such as SAH that require significant health resources.
Authors: Silvia G I Ozcariz; Carla de O Bernardo; Francieli Cembranel; Marco A Peres; David A González-Chica Journal: BMC Public Health Date: 2015-05-10 Impact factor: 3.295
Authors: Denise Rodrigues Bueno; Maria de Fátima Nunes Marucci; Luis Alberto Gobbo; Manuela de Almeida-Roediger; Yeda Aparecida de Oliveira Duarte; Maria Lucia Lebrão Journal: BMC Geriatr Date: 2017-03-20 Impact factor: 3.921
Authors: Ketevan Rtveladze; Tim Marsh; Laura Webber; Fanny Kilpi; David Levy; Wolney Conde; Klim McPherson; Martin Brown Journal: PLoS One Date: 2013-07-11 Impact factor: 3.240